Merrimack pharmaceuticals pipeline
Web7 nov. 2024 · Now, Peters said Merrimack is ending all research on MM-121, including a separate ongoing Phase 2 study. Instead, Merrimack will embrace a narrower pipeline centered around MM-310, an antibody-directed nanotherapeutic intended to reduce the toxicity of docetaxel, a cancer chemotherapy. MM-310 has its own problems, however. Web18 jan. 2016 · Merrimack’s platform should generate 3 important data readouts in 2016 and 3 more in 2024. Merger of Baxalta and Shire should not slow approval of Onivyde in the EU.
Merrimack pharmaceuticals pipeline
Did you know?
Web25 jun. 2024 · (Reuters) - Merrimack Pharmaceuticals Inc said on Monday it would stop developing its experimental treatment for pancreatic cancer after it failed to meet the main and secondary goals in a... Web11 okt. 2024 · Merrimack (MACK) focuses on the development of its two early-stage pipeline candidates, MM-121 and MM-310. The candidates have been progressing well …
Web12 dec. 2014 · CAMBRIDGE, Mass., Dec. 12, 2014 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc ... Merrimack Pharmaceuticals Presents Research on Innovative Pipeline for Patients With Breast Cancer at the ... Web9 nov. 2024 · CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 9, 2024-- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) today …
WebClosing in on Cancer. At Merus, we are clinically advancing leading-edge, targeted treatments to address the unmet needs of patients with various types of cancer. Utilizing our proprietary technology platforms, we are developing innovative multispecific antibody therapeutics, referred to as Multiclonics ®. WebPhotocure, The Bladder Cancer Company. Bladder cancer is a global challenge. By focusing on improving bladder cancer management, we are delivering transformative solutions that make a positive impact on the lives of hundreds of thousands of patients.
Web30 mei 2024 · CAMBRIDGE, Mass., May 30, 2024 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced the completion of its review of strategic alternatives, following which the...
Web4 apr. 2024 · CAMBRIDGE, Mass., April 4, 2024 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK ), an oncology company focused on biomarker … hiking trails friedrich wilderness parkWeb16 mei 2024 · Our pipeline of DNA Damage Response modulators includes novel inhibitors of ATR and WEE1. ATRN-119: Novel macrocyclic ATR inhibitor. Unique biomarkers identified for optimized patient selection; Differentiated, macrocyclic molecular structure; Potential for lower hematological toxicity versus other ATR inhibitors; Phase 1 clinical trial ... hiking trails from downtown crested butteWeb10 apr. 2024 · DelveInsight’s, “Soft Tissue Sarcoma Pipeline Insight 2024,” report provides comprehensive insights about 130+ companies and 130+ pipeline drugs in the Soft Tissue Sarcoma pipeline landscape. It covers the Soft Tissue Sarcoma pipeline drug profiles, including Soft Tissue Sarcoma clinical trials and nonclinical stage products. hiking trails full of brushWeb22 mei 2014 · These presentations showcase Merrimack's broad oncology pipeline. "ASCO is an exciting opportunity for us to share the first Phase 2 clinical data from our systems biology-driven MM-121 program. small water blisters feetWeb30 jun. 2024 · X4 Pharmaceuticals Announces $55 Million Private Placement Financing and Debt Facility Amendment Extending Interest-Only Period by up to 12 Months. BOSTON, June 30, 2024 (GLOBE NEWSWIRE) -- X4 ... small water birds ukWeb22 mei 2014 · CAMBRIDGE, Mass., May 22, 2014 -- Merrimack Pharmaceuticals, Inc. today announced it will present clinical data on four novel antibody cancer therapeutics at the 2014 American Society of Clinical... April 3, 2024 hiking trails front royal vaWeb6 nov. 2014 · CAMBRIDGE, MA, USA I November 6, 2014 I Merrimack Pharmaceuticals, Inc. today announced that the first patient has been enrolled in a Phase 1 clinical study of MM-398 (nanoliposomal irinotecan injection) in a highly concentrated formulation in patients with recurrent high grade glioma, a type of aggressive brain tumor with poor prognosis. hiking trails from moffat tunnel